Novartis Q2 beats estimates; FY2026 outlook reaffirmed

Novartis (NYSE:NVS) beat top-line and bottom-line estimates in the second quarter and reaffirmed its full-year 2026 outlook.

The Swiss drugmaker reported adjusted earnings per share of $2.04, above the consensus estimate of $1.95. Revenue came in at $13.2 billion, topping the $12.9 billion analysts had expected.

Novartis reaffirmed its 2026 guidance for mid-single-digit revenue growth and high-single-digit core operating income growth, both in constant currencies.

The results were driven by its key growth products, including heart drug Entresto and the psoriasis treatment Cosentyx. The company's innovative medicines segment posted sales of $11.4 billion, up 8% from a year earlier.

Novartis shares rose 1.2% in early trading following the release.